---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036281"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:58:19.719981+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Roivant Q1 net income $57.5M, cash $5.7B; pipeline advances in MG, DM, NIU

## Summary
- Net income of $57.5M vs net loss of $327.8M YoY; diluted EPS $0.12 vs ($0.38).
- Total revenue $55.1M, product revenue $18.4M from VTAMA; license/milestone $36.8M.
- Cash, cash equivalents and restricted cash $5.7B at June 30, 2024, reflecting $648M share repurchase.
- Immunovant completed enrollment in batoclimab pivotal MG trial; brepocitinib Phase 3 VALOR in DM completed enrollment.
- Priovant to initiate Phase 3 for brepocitinib in NIU; VTAMA PDUFA action expected Q4 2024.

## SEC filing metadata
- accession: 0001140361-24-036281
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124036281/0001140361-24-036281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124036281/ef20033756_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036281
- JSON: https://secwatch.observer/filing/0001140361-24-036281.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.